| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Vimian Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr34.95 |
| 52 Week High | kr36.00 |
| 52 Week Low | kr20.08 |
| Beta | 1.52 |
| 1 Month Change | 11.31% |
| 3 Month Change | 23.94% |
| 1 Year Change | 12.74% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.80% |
Recent News & Updates
Recent updates
Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 18
Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate
Apr 09Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital
Feb 13Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues
Jan 08Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching
Dec 03There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital
Nov 01Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 92% Above Its Share Price
Aug 27When Should You Buy Vimian Group AB (publ) (STO:VIMIAN)?
Jul 19Are Investors Undervaluing Vimian Group AB (publ) (STO:VIMIAN) By 27%?
May 19Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
Apr 04Calculating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)
Jan 06Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
Dec 09Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 38% Discount?
Aug 25We Like These Underlying Return On Capital Trends At Vimian Group (STO:VIMIAN)
Jun 18Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 34% Discount?
May 19Does This Valuation Of Vimian Group AB (publ) (STO:VIMIAN) Imply Investors Are Overpaying?
Feb 07Risks Still Elevated At These Prices As Vimian Group AB (publ) (STO:VIMIAN) Shares Dive 28%
Nov 30Shareholder Returns
| VIMIAN | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 4.0% | 1.1% | -0.9% |
| 1Y | 12.7% | -7.1% | 14.2% |
Return vs Industry: VIMIAN exceeded the Swedish Medical Equipment industry which returned -7.1% over the past year.
Return vs Market: VIMIAN underperformed the Swedish Market which returned 14.3% over the past year.
Price Volatility
| VIMIAN volatility | |
|---|---|
| VIMIAN Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: VIMIAN has not had significant price volatility in the past 3 months.
Volatility Over Time: VIMIAN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1,100 | Patrik Eriksson | vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
| VIMIAN fundamental statistics | |
|---|---|
| Market cap | kr18.26b |
| Earnings (TTM) | kr90.61m |
| Revenue (TTM) | kr3.82b |
201.5x
P/E Ratio4.8x
P/S RatioIs VIMIAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIMIAN income statement (TTM) | |
|---|---|
| Revenue | €334.95m |
| Cost of Revenue | €103.16m |
| Gross Profit | €231.79m |
| Other Expenses | €223.85m |
| Earnings | €7.94m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 15, 2024
| Earnings per share (EPS) | 0.015 |
| Gross Margin | 69.20% |
| Net Profit Margin | 2.37% |
| Debt/Equity Ratio | 57.4% |
How did VIMIAN perform over the long term?
See historical performance and comparison